The nice people at “Transfusion News” sent their update today. All very interesting, but I wish that science would make its mind up. Is convalescent plasma worth using or not? Opinion seems to be changing on a weekly basis…
March 9, 2022[Read More]Recent omicron variants of the SARS-CoV-2 virus have at least 32 changes in the spike protein relative to the original strain identified in Wuhan, rendering many monoclonal antibodies (e.g., sotrovimab and tixagevimab) developed against the Wuhan strain ineffective. Clinical trials, however, have shown that COVID-19 convalescent plasma (CCP) transfusions decrease the risk of hospitalization and mortality given to outpatients and immunosuppressed individuals with COVID-19, respectively.
March 9, 2022 | BBGuy Podcast [Listen Now]CE Episode! Plasma product names are confusing, but few are as misunderstood as Liquid Plasma. Dr. Chris Gresens explains why LP might be perfect for your transfusion service.
March 2, 2022 [Read More]Organ transplant recipients with group O blood type often have to wait at least twice as long as group A, B or AB recipients and have a 20% greater risk of mortality while on the transplant waitlist. Similar to RBCs, enzymatic removal of the terminal sugar epitope (α-galactose or N-acetyl-galactosamine) on A and B antigen oligosaccharides would convert these antigens to the universal group O blood type and expand the compatible organ donor pool.